ANRO
Price
$1.80
Change
-$0.05 (-2.70%)
Updated
Apr 4 closing price
Capitalization
48.73M
44 days until earnings call
NUVL
Price
$65.74
Change
-$2.58 (-3.78%)
Updated
Apr 4 closing price
Capitalization
4.71B
33 days until earnings call
Ad is loading...

ANRO vs NUVL

Header iconANRO vs NUVL Comparison
Open Charts ANRO vs NUVLBanner chart's image
Alto Neuroscience
Price$1.80
Change-$0.05 (-2.70%)
Volume$483.84K
Capitalization48.73M
Nuvalent
Price$65.74
Change-$2.58 (-3.78%)
Volume$582.53K
Capitalization4.71B
ANRO vs NUVL Comparison Chart
Loading...
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANRO vs. NUVL commentary
Apr 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Hold and NUVL is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 06, 2025
Stock price -- (ANRO: $1.80 vs. NUVL: $65.74)
Brand notoriety: ANRO and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 144% vs. NUVL: 114%
Market capitalization -- ANRO: $48.73M vs. NUVL: $4.71B
ANRO [@Biotechnology] is valued at $48.73M. NUVL’s [@Biotechnology] market capitalization is $4.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $296.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, ANRO is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 3 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • ANRO’s TA Score: 3 bullish, 6 bearish.
  • NUVL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than ANRO.

Price Growth

ANRO (@Biotechnology) experienced а -20.70% price change this week, while NUVL (@Biotechnology) price change was -10.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.00%. For the same industry, the average monthly price growth was -16.69%, and the average quarterly price growth was -18.23%.

Reported Earning Dates

ANRO is expected to report earnings on May 20, 2025.

NUVL is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-11.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($4.71B) has a higher market cap than ANRO($48.7M). NUVL YTD gains are higher at: -16.019 vs. ANRO (-57.447). ANRO has higher annual earnings (EBITDA): -55.61M vs. NUVL (-280.37M). NUVL has more cash in the bank: 1.12B vs. ANRO (182M). ANRO (0) and NUVL (0) have equivalent revenues.
ANRONUVLANRO / NUVL
Capitalization48.7M4.71B1%
EBITDA-55.61M-280.37M20%
Gain YTD-57.447-16.019359%
P/E RatioN/AN/A-
Revenue00-
Total Cash182M1.12B16%
Total Debt16.8MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ANRONUVL
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 25 days ago
88%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DRV32.233.96
+14.01%
Direxion Daily Real Estate Bear 3X ETF
VBND44.00-0.02
-0.04%
Vident U.S. Bond Strategy ETF
CLSE20.12-0.98
-4.64%
Convergence Long/Short Equity ETF
OCEN18.82-1.10
-5.53%
NYLI Clean Oceans ETF
IVLU27.51-2.01
-6.81%
iShares Edge MSCI Intl Value Factor ETF

ANRO and

Correlation & Price change

A.I.dvisor tells us that ANRO and XTLB have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANRO and XTLB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
-2.70%
XTLB - ANRO
30%
Poorly correlated
+3.25%
NUVL - ANRO
28%
Poorly correlated
-3.78%
PRME - ANRO
27%
Poorly correlated
-12.42%
GUTS - ANRO
26%
Poorly correlated
-1.75%
CYCC - ANRO
26%
Poorly correlated
-6.96%
More